DEFA14A: BioLife Solutions Addresses Material Weaknesses and Outlines 2024 Remediation Plan

BioLife Solutions is actively addressing material weaknesses identified in its FY23 SOX compliance program, focusing on system implementation, internal controls, and resource expertise.

Summary

• BioLife Solutions delivered an investor presentation on July 26, 2024, addressing material weaknesses identified in its FY23 SOX compliance program.
• The company acquired six private companies between 2019 and 2021 and became fully SOX 404(b) compliant in Q2 2021.
• Material weaknesses were identified in the general control environment, IT change management and segregation of duties, and procure-to-pay and revenue controls.
• In 2023, the company redesigned controls, implemented 48 additional internal control procedures, and trained personnel.
• The accounting system for one additional subsidiary was transitioned to NetSuite in mid-2023, with all entities transitioned by July 1, 2023, except for Global Cooling and CBS, which are planned for divestiture.
• A new ERP implementation consulting team and a new internal audit consulting team were hired in Q4 2023.
• The company is working to have full remediation in 2024, which is a top priority for management, the Audit Committee, and the full Board.
• Global Cooling, Inc. was divested in April 2024, and the CBS divestiture is in process.

Sentiment

Score: 6

Explanation: The document highlights both positive steps taken to address material weaknesses and the negative identification of those weaknesses. The active remediation efforts and investment in resources suggest a commitment to improvement, but the existence of material weaknesses tempers the overall sentiment.

Positives

• BioLife Solutions is actively addressing the identified material weaknesses with a comprehensive remediation plan.
• The company has invested in additional resources, including hiring new personnel and consulting teams, to improve internal controls.
• The executive team and board are prioritizing SOX remediation, with monthly updates provided to the board and quarterly town hall meetings emphasizing the importance of controls.
• The company has divested Global Cooling, Inc. and is in the process of divesting CBS, which were previously out of scope for SOX testing.

Negatives

• BioLife Solutions identified material weaknesses in its FY23 SOX compliance program.
• There was insufficient time to demonstrate full remediation of controls related to the effective control environment and process-level controls in certain financial statement areas in 2023.
• Joydeep Goswami attended slightly less than 75% of meetings in 2023 due in part to overlapping commitments as CFO of Illumina.

Risks

• Failure to fully remediate the identified material weaknesses could lead to further issues with SOX compliance and financial reporting.
• Delays in system implementation and divestitures could impact the company's ability to achieve its remediation goals.
• The company's reliance on manual controls due to a lack of ERP and system integration poses a risk to the effectiveness of internal controls.

Future Outlook

The company is working diligently to have full remediation in 2024 and this is top priority of the management team, Audit Committee, and full Board.

Management Comments

• The Company is working diligently to have full remediation in 2024 and this is top priority of the management team, Audit Committee, and full Board.
• Tone at the top from the board and management (monthly SOX updates provided to the board, CEO/CFO quarterly townhall meetings emphasizing importance of controls).

Industry Context

BioLife Solutions operates in the bioproduction tools and services market for cell and gene therapies and the broader biopharma market, where SOX compliance and strong internal controls are critical for maintaining investor confidence and regulatory compliance.

Comparison to Industry Standards

• SOX 404(b) compliance is a standard requirement for publicly traded companies in the United States, ensuring the effectiveness of internal controls over financial reporting.
• Companies like Thermo Fisher Scientific, Danaher Corporation, and Sartorius AG, which also operate in the life sciences and biopharma industries, are expected to maintain robust internal control environments and comply with SOX regulations.
• The identified material weaknesses suggest that BioLife Solutions' internal controls were not fully aligned with industry best practices in FY23, but the company is taking steps to address these issues and improve its compliance posture.

Management Changes

Stakeholder Impact

• Shareholders: The remediation of material weaknesses is crucial for maintaining investor confidence and ensuring accurate financial reporting.
• Employees: Training and new policies will impact employees across various departments.
• Customers: Improved internal controls can lead to more reliable service and product delivery.
• Suppliers: Procure-to-pay controls will impact supplier relationships and payment processes.

Next Steps

• Implement NetSuite modules to address specific issues.
• Redesign controls, including controls to be automated through system implementations.
• Develop more robust policies and procedures.
• Training for rank and file on end-to-end processes.
• Complete the divestiture of CBS.

Key Dates

Keywords

SOX compliance, material weaknesses, remediation plan, internal controls, NetSuite, divestiture, ERP implementation, financial reporting, BioLife Solutions